Turnstone Biologics (NASDAQ:TSBX – Get Free Report) had its target price reduced by Bank of America from $12.00 to $10.00 in a note issued to investors on Monday, Benzinga reports. The firm presently has a “buy” rating on the stock.
Turnstone Biologics Trading Up 2.7 %
TSBX stock traded up $0.02 during midday trading on Monday, hitting $0.78. 405,815 shares of the company’s stock were exchanged, compared to its average volume of 197,891. Turnstone Biologics has a 12-month low of $0.73 and a 12-month high of $12.16. The firm has a 50 day moving average price of $2.44 and a 200-day moving average price of $2.78. The stock has a market capitalization of $18.09 million and a price-to-earnings ratio of -0.08.
Turnstone Biologics (NASDAQ:TSBX – Get Free Report) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.08). On average, sell-side analysts forecast that Turnstone Biologics will post -3.44 EPS for the current fiscal year.
Institutional Inflows and Outflows
About Turnstone Biologics
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.
Featured Articles
- Five stocks we like better than Turnstone Biologics
- What is a Death Cross in Stocks?
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- Top Biotech Stocks: Exploring Innovation Opportunities
- 2 Option Strategies to Maximize Profits in a Bear Market
- What Investors Need to Know About Upcoming IPOs
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for Turnstone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turnstone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.